Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical Holdings Group’s subsidiary, Xuanzhu Biopharm, has received drug registration approval from China’s National Medical Products Administration for its innovative drug, Dirozalkib Tablets, aimed at treating ALK-positive advanced non-small cell lung cancer. This approval marks a significant milestone in Xuanzhu Biopharm’s R&D pipeline, offering a breakthrough treatment option with notable clinical advantages, including rapid action, superior efficacy, and improved safety profile. The drug is expected to enhance the quality of life for patients and support the ‘Healthy China 2030’ cancer prevention and control goals, amidst a growing market for ALK inhibitors in China.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical Holdings Group, is an innovative pharmaceutical company based in China with a global outlook. It focuses on major diseases such as digestion, oncology, and non-alcoholic steatohepatitis. The company is dedicated to the research, development, production, and commercialization of Class 1 drugs with proprietary intellectual property rights. Xuanzhu Biopharm boasts a first-class R&D team and operates two R&D platforms: small molecule chemistry and large molecule biologics, driving innovation and development across a diverse product pipeline.
Average Trading Volume: 127,858,212
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.9B
Learn more about 0460 stock on TipRanks’ Stock Analysis page.